Navigation Links
NDO Receives FDA 510(K) Clearance for Plicator II(TM)
Date:9/20/2007

Strengthens Position as the Global Leader in Endoscopic Anti-Reflux Surgery

MANSFIELD, Mass., Sept. 20 /PRNewswire/ -- NDO Surgical, Inc. (NDO) announced that the US Food and Drug Administration (FDA) cleared the Company's Plicator II(TM) multiple implant technology for immediate sale and distribution. Plicator II technology offers improved outcomes for harder-to-treat gastroesophageal reflux disease (GERD) patients.

"This clearance and the subsequent launch of next-generation Plicator(R) technology strengthen our global leadership position in endoscopic anti-reflux surgery," said Bernard Haffey, President and CEO of NDO. "More patients can now choose the Plicator procedure with confidence in its associated safety and efficacy."

FDA clearance of the new Plicator technique was based on agency review of a multi-center, forty patient clinical trial in which eighty percent (80%) of treated patients experienced superior GERD symptom control at 6 months post-treatment. Seventy percent (70%) of treated patients recorded 6-month GERD-HRQL (health-related quality of life) scores that were better than the scores recorded while patients were being treated for GERD with proton pump inhibitor (PPI) medications.

"Plicator technology is currently the best endoluminal GERD treatment on the market and occupies a critical place in our treatment algorithm," said Lee Swanstrom, MD, Program Director of Minimally Invasive Surgery at Legacy Health System in Portland, Oregon. "For selected reflux patients, Plicator affords excellent symptom relief and normalized acid exposure. I look forward to treating an even larger segment of my GERD patients by incorporating the Plicator II multiple implant technique into our practice."

In addition, the study demonstrated significantly reduced esophageal acid exposure, improved esophageal manometry and lowered esophagitis scores together with a markedly reduced dependency on GERD medications. Results achieved in this s
'/>"/>

SOURCE NDO Surgical, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Infant receives first bloodless liver transplant
2. British MPs Say Prostate Cancer Receives Low Priority in the NHS
3. Fifth US Patient Receives Artificial Heart
4. Northfield Labs Receives FDA Comments
5. Abbott Receives CE Mark Certification
6. Zactima Receives Fast Track Designation By The FDA
7. East London Receives World Class New Private Hospital Facility
8. Brinda Karat Receives Legal Notice over Ramdev Issue
9. Quake-Hit Pakistan Receives 30 Field Hospitals From Cuba
10. Medtronic’s Insulin Pump Receives Regulatory Approva
11. Aurobindo Receives Approval from USFDA for anti-AIDS drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2008)...rter financial results -, LAVAL, QC, July 25 /PRN...DAQ: DDSS) today announced that it will host a con... to discuss its second quarter 2008,financial resu... financial,results via news release at approximate...nce call by telephone, dial 416-646-3095 or,1-800-...
(Date:7/25/2008)...erweight or obese is not only a personal issue tha... issue that impacts other people in society. A new...eveals that the extra Medicare cost associated wit...ant financial burden on tax payers, costing up to ...current Medicare population. , The article,s fi...
(Date:7/25/2008)...Fourth Annual Physician On-Call Pay ...swire/ -- Sullivan, Cotter and Associates, Inc.,ha...on-call pay rates and,practices, the 2008 Physicia...th data from 132 healthcare organizations nationwi...ates paid for 33 physician specialty areas along,w...
(Date:7/25/2008)...ire/ -- Sagent Pharmaceuticals, Inc.,a privately-...nced that it,has launched amiodarone HCl injection...e treatment and prophylaxis of frequently recurrin...table ventricular,tachycardia -- a potentially lif...arone HCl injection will be available immediately ...
Breaking Medicine News(10 mins):Health News:Labopharm to host conference call Friday, August 8, 2008 at 8:30 A.M. (ET) 2Health News:Hospital Expenditures for Physician On-Call Pay Rates Nearly Double 2Health News:Hospital Expenditures for Physician On-Call Pay Rates Nearly Double 3Health News:Sagent Pharmaceuticals Launches Amiodarone HCl Injection, USP 2Health News:Sagent Pharmaceuticals Launches Amiodarone HCl Injection, USP 3
...imed in treating AIDS patients using a herbal conc...se in white blood cell count. // Dr P L Meenakshi... reporters that the Herbal medicine helped HIV pa...(lymphocyte 4 - white blood cell) count increased ...
...lous kitten, when it comes to protecting her hands...f young ladies who drape themselves all over the r...at she would rather quit singing forever than lose...she gets really annoyed when girls flirt with her ...
...ded a grant of $30,000 to Medical College of Georg...understand the usefulness of online information sy...hether an online information system woulc be helpu...G was among 60 institutions invited to apply and t...
...essor and director of research in Virginia Commonw...ne reported that it will be fruitful // and more l...oving the medical facilities and provided the exis...ress allocates funds to the National Institute of ...
Other Medicine News:Health News:Online information system for patients 2Health News:Stop spending on new treatments; allocate funds to improve the existing treatments. 2
(Date:7/24/2008)... New JIT Enrollment Program Speeds Oncology... Pharmatech, Inc., a Research Management,Organizat...ceutical,companies to provide research and site ma...the Just-in-Time (JIT) enrollment strategy. The ne...: follicular Non-Hodgkin,s,Lymphoma, Metastatic Br...
(Date:7/24/2008)... NEW YORK, July 24 /- Mac...y announced results of a Phase 2 clinical trial,in...multi-center,open-label efficacy and safety study...treatment of onychomycosis (nail fungus). The comp...complete cure" defined as,negative mycology (negat...
(Date:7/23/2008)... - Nexavar is First Approved Systemic Therapy to... Calif., July 23 /-,Bayer H..., Inc. (Nasdaq:,ONXX) today announced that The New...a Phase 3 trial demonstrating that Nexavar(R) (sor...th by 31 percent in patients with,unresectable hep...
(Date:7/23/2008)... SEATTLE, July 23 /- Sound Pharmace...g Application with the FDA for the clinical,testin...prevention of,chemotherapy induced hearing loss or... SPI-3005, will be tested in advanced stage lung c...platinum based chemotherapy.,This marks the second...
Breaking Medicine Technology:Pharmatech, Inc. Contracts for Five New Just-in-Time Clinical Trials 2MacroChem Announces Phase 2 Data for EcoNail(R) in the Treatment of Onychomycosis 2MacroChem Announces Phase 2 Data for EcoNail(R) in the Treatment of Onychomycosis 3MacroChem Announces Phase 2 Data for EcoNail(R) in the Treatment of Onychomycosis 4MacroChem Announces Phase 2 Data for EcoNail(R) in the Treatment of Onychomycosis 5The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 2The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 3The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 4The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 5The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 6Sound Pharmaceuticals Files Second IND with the FDA for the Prevention of Chemotherapy Induced Hearing Loss in Advanced Stage Cancer 2Rocky water source 3607 1Rocky water source 3607 2Sex offenders register provides limited protection for children 21576 1Sex offenders register provides limited protection for children 21576 2Raloxifene Cuts Risk of Certain Type of Breast Cancer 21573 1Raloxifene Cuts Risk of Certain Type of Breast Cancer 21573 2Harris Corporations Jim Traficant Addresses Florida Agency for Health Care Administration 21570 1Harris Corporations Jim Traficant Addresses Florida Agency for Health Care Administration 21570 2
Ruschelit® PVC. Siliconized. Stainless steel spiral reinforced. Murphy eye. High volume/low pressure cuff. Connector is permanently fixed into the tube. X-ray opaque. Graduated. Single use. Steri
...ser resistant foam surrounds the lower 17cm of tub...16") long, Single Use. The tracheal tube is design...within the operating site, while maintaining contr...ser-guard of approx. 17cm in length proximal to th...
Tube for Left Bronchus - Ruschelit™ PVC. Color coded for easy identification of ports, balloons and 15mm connectors. High volume/low pressure cuffs. X-ray opaque line. Graduated. Single use. St
...l Anesthetic, ,Designed for adolescent and adult ...tional lumen and injection port for spray applicat...., ,SHERIDAN offers three endotracheal tubes desi...oring or medication delivery without additional ad...
Medicine Products: